Heart Failure with Preserved Left Ventricular Ejection Fraction

S.M. Коzhukhov, О.M. Pаrkhomenko


Heart failure with preserved left ventricular ejection fraction (HF-PEF) is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase stroke volume by the Frank–Starling mechanism. Prognosis is almost as severe as for the heart failure with reduced ejection fraction (HF-REF), in part reflecting co-morbidities. Before the diagnosis of HF-PEF is made, non-cardiac etiologies must be excluded. Due to the non-specific nature of heart failure symptoms, it is essential to search for objective evidence of diastolic dysfunction which, in the absence of invasive data, is confirmed by echocardiography and demonstration of signs of elevated LV filling pressure, impaired LV relaxation or increased LV diastolic stiffness. Treatment of HF-PEF is symptomatic, with similar drugs as in HF-REF.


heart failure; diastolic function; ejection fraction


Abozguia K., Elliott P., McKenna W. et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy // Circulation. — 122(16). — 1562-1569.

Ahmed M.W., Rich M.W., Fleg J.L. et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial // Circulation. — 2006. — 114. — 397-403.

Aurigemma G.P., Gaasch W.H. Clinical practice in diastolic heart failure // N. Engl. J. Med. — 2004. — 351. — 1097-1105.

Bader H., Garrigue S., Lafitte S. et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients // J. Am. Coll. Cardiol. — 2004. — 43. — 248-256.

Bonow R.O., Leon M.B., Rosing D.R. et al. Effects of verapamil and propranolol on left ventricular systolic function and diastolic fil­ling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise // Circulation. — 1982. — 65. — 1337-1350.

Campbell J.E., Janicki J.S., Weber K.T. Temporal differen­ces in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone // J. Mol. Cell. Cardiol. — 1995. — 27. — 1545-1560.

Carson P., Massie B.M., McKelvie R. et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design // J. Card. Fail. — 2005 Oct. — 11(8). — 576-85.

Daniel K.R., Wells G., Stewart K. et al. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure // Congest. Heart Fail. — 2009. — 15(2). — 68-74.

Ferreira R.C., Carvalho R.F., Pires I.F., Moreira A.L. The role of titin in the modulation of cardiac function and its pathophysiological implications. Serviço de Fisiologia Faculdade de Medicina da Universidade do Porto, Portugal // Circ. Heart Fail. — 2010. — 3(5). — 588-595.

Fukuta H., Sane D.C., Brucks S., Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report // Circulation. — 2005. — 19, 112(3). — 357-363.

Guazzi M., Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development // Curr. Med. Chem. — 2007. — 14. — 2181-2191.

Guazzi M., Vicenzi M., Arena R., Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study // Circulation. — 2011. — 124. — 164-174.

Ha J.W., Choi D., Park S. et al. Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction // Heart. — 2009. — 95. — 490-494.

Hernandez A., Hammill B., O’Connor C. et al. Clinical Effectiveness of Beta-Blockers in Heart Failure. Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry // J. Am. Coll. Cardiol. — 2009. — 53(2). — 184-192.

Inglis S.C., McMurray J.J., Böhm M. et al.; CORONA Study Group. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosu­vastatin Multinational Trial in Heart Failure trial (CORONA) // Eur. J. Heart Fail. — 2010. — 12(7). — 698-705.

Jessup M., Abraham W.T., Casey D.E. et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardio­logy Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation // Circulation. — 2009. — 119. — 1977-2016.

Lam C.S., Roger V.L., Rodeheffer R.J. et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study // J. Am. Coll. Cardiol. — 2009. — 53. — 1119-1126.

Leong D.P., De Pasquale C.G., Selvanayagam J.B. Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging // JACC Cardiovasc. Imaging. — 2010. — 3(4). — 409-420.

Little W.C., Zile M.R., Kitzman D.W. et al. The effect of ala­gebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure // J. Card. Fail. — 2005. — 11. — 191-195.

Maeder M.T., Kaye D.M. Heart failure with normal left ventricular ejection fraction // J. Am. Coll. Cardiol. — 2009. — 53. — 905-918.

McMurray J., Adamopoulos S., Anker S. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC // Eur. Heart J. — 2012. — Vol. 33. — P. 1787-1847.

Mottram P.M., Haluska B., Leano R. et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure // Circulation. — 2004. — 110. — 558-565.

Neubauer S. The failing heart — an engine out of fuel // N. Engl. J. Med. — 2007. — 356(11). — 1140-1151.

Oh J.K., Hatle L., Tajik A.J., Little W.C. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography // J. Am. Coll. Cardiol. — 2006. — 47. —


Owan T., Hodge D., Herges R. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction // N. Engl. J. Med. — 2006. — 355. — 251-259.

Owen T.E., Redfield M.M. Epidemiology of diastolic heart failure // Prog. Cardiovasc. Dis. — 2005. — 47. — 320-332.

Paulus W.J., van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth! // J. Am. Coll. Cardiol. — 2010. — 55(6). — 526-537.

Sanderson J.E. Heart failure with a normal ejection fraction // Heart. — 2007. — 93. — 155–158.

Tan Y.T., Wenzelburger F., Lee E. et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion // J. Am. Coll. Cardiol. — 2009. — 54(1). — 36-46.

Weber K.T. Fibrosis and hypertensive heart disease // Curr. Opin. Cardiol. — 2000. — 15. — 264–272.

Westermann D., Kasner M., Steendijk P. et al. Role of left ventricular stiffness in heart failure with normal ejection fraction // Circulation. — 2008. — 117(16). — 2051-2060.

Zile M.R., Anand I.S., Gaasch W.S. et al. For the I-PRESERVE Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial // Circulation. — 2010. — 121. — 1393-1405.

DOI: https://doi.org/10.22141/2224-0586.1.72.2016.74477

Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта